The medical history of cancer began millennia ago. Historical findings of patients with
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …

Abstract The NCI-MATCH (Molecular Analysis for Therapy Choice) trial (NCT02465060) was
launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

Stem cell factor (SCF) is a dimeric molecule that exerts its biological functions by binding to
and activating the receptor tyrosine kinase c-Kit. Activation of c-Kit leads to its …

Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of
personalized treatment for cancer patients. The nearly simultaneous discovery of a …

G-quadruplexes are four-stranded DNA structures that are over-represented in gene
promoter regions and are viewed as emerging therapeutic targets in oncology, as …

c-Kit, a receptor tyrosine kinase, is involved in intracellular signaling, and the mutated form
of c-Kit plays a crucial role in occurrence of some cancers. The function of c-Kit has led to the …

Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …

Background Constitutive activation of KIT receptor tyrosine kinase is critical in the
pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine …

Most gastrointestinal stromal tumors (GISTs) have activating mutations in the KIT receptor
tyrosine kinase, and most patients with GISTs respond well to Gleevec, which inhibits KIT …